Join our daily newsletter At The Bell to receive exclusive market insights
- Telix Pharmaceuticals (TLX) finishes recruitment for its study following the dosing of its tenth patient for treatment of recurrent glioblastoma multiforme (GBM)
- Telix has been studying the efficacy of TLX101 in recurrent GBM, a highly aggressive cancer that progresses rapidly, with few effective treatment options
- The company says it is highly encouraged by the safety profile of this single arm dose-escalation study, where different dosing regimens have been combined with external radiation therapy
- The company says a follow up study is currently in the works to accelerate the development of TLX101
- Telix Pharmaceuticals was down 11.5 per cent, trading at $5.67 at 12:25 pm AEST
Telix Pharmaceuticals (TLX) has stopped recruitment for its study following the dosing of its tenth patient.
Telix finalised recruitment for its IPAX-1 Ph I/II study of TLX101 study in combination with external beam radiation therapy in recurrent glioblastoma multiforme (GBM).
TLX101 is under evaluation for the treatment of recurrent GBM at five clinical sites across Australia and Europe. Recurrent GBM is a highly aggressive cancer that progresses rapidly, with few effective treatment options.
TLX101 is a systemically administered, molecularly targeted radiation investigational asset that targets an amino acid which is typically over-expressed in patients with GBM. The treatment has already been granted orphan drug designation in the US and Europe.
The company says interim analysis of safety and preliminary efficacy has encouraged further study in front-line therapy, where radiation therapy is more extensively used.
“We are highly encouraged by the safety profile of this single arm dose-escalation study, where different dosing regimens have been combined with external radiation therapy,” said Telix Chief Medical Officer Dr Colin Hayward.
“Whilst a small study of ten patients, promising overall survival and anti-tumour response observed from longitudinal imaging supports the decision to progress this candidate into an earlier line of therapy.”
The company says a follow up study is currently in the works to accelerate the development of TLX101.
Telix Pharmaceuticals was down 11.5 per cent, trading at $5.67 at 12:25 pm AEST.
